SCHEMBL6097579

SCHEMBL6097579

O=C1C=C(c2cn(S(=O)(=O)c3cccc([N+](=O)[O-])c3)c3ccc(OCc4ccccc4)cc23)C(=O)N1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.47
HTR6 P50406 4/20 0.46
CTSV O60911 2/20 0.44
CTSL P07711 2/20 0.44
PSEN1 P49768 1/20 0.43
PSEN2 P49810 1/20 0.43
APH1B Q8WW43 1/20 0.43
NCSTN Q92542 1/20 0.43
APH1A Q96BI3 1/20 0.43
PSENEN Q9NZ42 1/20 0.43
TNFSF11 O14788 5/20 0.40
NR3C1 P04150 1/20 0.39
MAPT P10636 2/20 0.39
ALDH1A1 P00352 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TNF P01375 1/20 0.38
CNR2 P34972 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6099113 0.93 HTR6 (0.50) ARHTR6CTSVCTSLMAPT
SCHEMBL6099154 0.85 HTR6 (0.52) ARHTR6MEN1KMT2A
SCHEMBL6097457 0.78 HTR6 (0.45) HTR6
SCHEMBL6098592 0.75 PPARD (0.48) ALDH1A1LMNA
SCHEMBL6099550 0.75 HTR6 (0.46) HTR6CA2CA9
SCHEMBL6098735 0.73 BAZ2B (0.48) HTR6MEN1KMT2ACNR2
SCHEMBL6097466 0.73 MAOB (0.44) MEN1KMT2ACNR2
SCHEMBL6099720 0.73 PPARD (0.50) HTR6SMN1; SMN2
SCHEMBL19737474 0.73 HTR6 (0.51) HTR6TNFSF11
SCHEMBL6100670 0.72 MAOB (0.43) HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7129250-B2 Neuroprotective and anti-proliferative compounds AEGERA THERAPEUTICS INC. (CA) 2006-10-31 US disclosed
US-20040220202-A1 Neuroprotective and anti-proliferative compounds AEGERA THERAPEUTICS INC. (CA) 2004-11-04 US disclosed
US-20040102467-A1 Neuroprotective and anti-proliferative compounds AEGERA THERAPEUTICS INC. (CA) 2004-05-27 US disclosed
EP-1283836-A2 NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS Aegera Therapeutics Inc. (CA) 2003-02-19 EP disclosed
WO-2001087887-A2 NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS AEGERA THERAPEUTICS INC. (CA) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220202-A1 Neuroprotective and anti-proliferative compounds NLN, MKI67, BDNF AR 2389/4885HTR6 765/4885CTSV 1901/4885
US-20040102467-A1 Neuroprotective and anti-proliferative compounds MKI67, NLN, BDNF AR 2521/4885HTR6 883/4885CTSV 2167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.